Trial Profile
An open-label safety study of Botulinum toxin A short interval therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2018
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Blepharospasm; Dystonia; Meige syndrome; Torticollis; Writers' cramp
- Focus Adverse reactions
- 08 Mar 2018 New trial record